Advertisement

Drug resistance: Prevalence and clinical implications during the treatment of chronic hepatitis C infection

Authors

  • Jean-Michel Pawlotsky M.D., Ph.D.

    Corresponding author
    1. From the National Reference Center for Viral Hepatitis B, C, and Delta, Department of Virology, Henri Mondor Hospital, Paris-Est University, Créteil, France; and Unit 955, National Institute of Health and Medical Research, Créteil, France
    • National Reference Center for Viral Hepatitis B, C, and Delta, Department of Virology, Henri Mondor Hospital, Paris-Est University, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France
    Search for more papers by this author

  • Potential conflict of interest: Jean-Michel Pawlotsky has received research grants from Gilead and Roche. He has served as an advisor for Abbott, Achillion, Anadys, Biotica, Boehringer-Ingelheim, Bristol-Myers Squibb, DebioPharm, Gilead, Glaxo-SmithKline, Idenix, Inhibitex, Janssen-Cilag/Tibotec, Madaus-Rottapharm, Merck/Schering-Plough, Novartis, Pfizer, Pharmasset, Roche, Sanofi-Aventis, Vertex, and Virco.

Abstract

Watch the interview with the authors

Answer questions and earn CME

Ancillary